Commercialization Engine
Vainture Signal
Should we commercialize this?
In about three minutes, we tell you whether a disclosure has real commercial legs — naming the actual market, real competitors, named investors, and likely funding sources.
What we tell you
Whether this venture has commercial legs — and the named markets, competitors, investors, and funding programs that back the answer.
What you put in
A disclosure: structured intake form or paste an existing patent abstract, invention disclosure summary, or US/EP/WO patent number.
What you get back
A Vainture Signal Report — Proceed / Pivot / Decline verdict, 0–100 score, six dimension scores, named entities, ranked next steps.
Use it when
A new disclosure lands, an investor asks for diligence depth, or you need to triage which inventions deserve a spinout conversation.
What it does
Six dimensions, scored against real data.
Every Signal evaluation runs the same six-dimension analysis with live web search. Real markets. Real competitors. Real investors. Real funding sources — not training-data approximations.
Market Opportunity
25%Total addressable market, serviceable market, growth rate, key drivers and barriers. Real numbers from current sources, not training data.
Competitive Landscape
20%Named competitors with their approach, differentiation analysis, competitive risk assessment. We name companies, not categories.
Regulatory Pathway
15%Likely FDA pathway, estimated timeline and cost, expedited options (Breakthrough, Fast Track, Orphan), key regulatory risks.
Investor Landscape
15%Named VC firms, family offices, and strategic investors that have funded comparable companies. Recent deals, typical check sizes, stages.
Strategic Partners
15%Named pharma, biotech, medtech, and device companies that would be logical licensing partners or acquirers. Recent deal activity.
Public Funding
10%Named NIH FOAs, CPRIT programs, DARPA, BARDA, NSF, foundation grants, SBIR/STTR. Award amounts and deadlines where available.
Who it's for
Built for the commercialization gate
Most TTOs answer two distinct questions about every disclosure: should we file, and should we spin this out? Vainture Signal answers the second — at a depth that previously required weeks of analyst time per disclosure.
TTO Business Development
Evaluate the spinout question on every disclosure with the same six-dimension framework, not whichever analyst happens to own it.
Seed and Series A Investors
Receive structured commercialization reports from institutional pipelines. The same evidence base in seconds, not in deck-deep diligence cycles.
Faculty Founders
See a realistic commercialization picture early — what markets, what competitors, what investors fund this shape of company.
The output
A Vainture Signal Report.
Every evaluation produces a structured report — not a chat transcript. Executive summary, market opportunity, competitive landscape, regulatory pathway, named investors, named partners, named funding programs, ranked next steps.
Verdict
Proceed / Pivot / Decline
An honest recommendation backed by the evidence behind it. Most evaluations should not advance. Some clearly should. Both deserve the same evidence.
Score
0–100 commercialization score
A fixed-weight aggregate of the six dimensions. Transparent weighting. Score gates the recommendation.
Named entities
Real markets, real names
Specific TAM/SAM figures. Named competitors. Named VCs with recent deals. Named pharma partners. Named NIH/CPRIT/SBIR programs with deadlines.
Score your next disclosure in three minutes.
Vainture Signal runs standalone, or alongside Vainture Patent as part of a full evaluation.